查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1844414

神經復健設備市場按設備類型、應用、最終用戶、技術和年齡層別分類－2025-2032年全球預測

Neurorehabilitation Devices Market by Device Type, Application, End User, Technology, Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，神經復健設備市場規模將達到 26.2 億美元，複合年成長率為 7.97%。

主要市場統計數據
基準年 2024 14.2億美元
預計年份：2025年 15.3億美元
預測年份：2032年 26.2億美元
複合年成長率 (%) 7.97%

全面審視當代臨床壓力、相關人員的期望以及技術主導的神經復健設備採用和護理服務重塑之路。

神經復健設備正處於臨床需求與快速技術進步的交匯點，其發展動力源於恢復神經系統疾病患者的功能、減輕殘疾程度並提高生活品質的需求。臨床醫生日益需要能夠整合精準診斷、適應性治療方法和可衡量療效的解決方案，而支付方和醫療服務提供者則要求透過提高功能獨立性和降低長期照護成本來證明其價值。因此，開發人員正優先考慮互通性、以使用者為中心的設計和循證實踐，以縮短從技術創新到臨床應用的路徑。

目前，重點正轉向能夠實現跨不同醫療環境（從急診醫院到門診復健中心再到居家照護）的連續性護理和遠端監測的設備。因此，監管策略、臨床檢驗和真實世界表現數據正成為商業性成功的關鍵決定因素。在此轉變過程中，相關人員必須平衡漫長的研發週期和複雜的報銷環境，以及人們對個人化和可擴展臨床工作流程日益成長的期望。

融合技術、分散式護理模式和以價值主導的證據要求如何推動神經復健設備開發和交付領域的模式轉移

神經復健領域正經歷多重變革時期，重塑治療方法的研發、報銷和實施方式。感測、驅動和機器學習技術的進步，使得設備能夠提供適應性治療方案，並近乎即時地回應患者的復原進展。同時，機器人技術、神經調控、腦機介面和身臨其境型虛擬環境的融合，正將治療的可能性推向傳統框架之外，從而實現針對運動、認知和感覺功能恢復的多模態干涉。

與此同時，臨床實踐模式正朝著分散式醫療模式發展。這種轉變推動了對輕鬆易用設備的需求，這些設備能夠支援居家治療和臨床醫生指導的遠距會診。支付者和醫療系統正在應對人口老化和慢性神經系統疾病盛行率上升的問題，優先考慮那些能夠帶來長期功能改善並降低後續成本的干涉措施。因此，產品開發藍圖強調報銷策略、追蹤長期療效以及累積證據以檢驗持續的臨床有效性。最終，這些因素共同加速了從個別設備轉變為整合式醫療平台的轉變，從而建構一個將患者、臨床醫生和數據連接起來的連續性醫療生態系統。

2025年關稅調整對供應鏈、籌資策略和區域製造業的影響：神經復健設備相關人員的考量

2025年實施的關稅和貿易措施為依賴跨境供應鏈取得零件和成品設備的製造商、供應商和醫療保健系統帶來了新的營運和策略考量。對於進口專用電子產品、感測器和驅動系統的公司而言，關稅帶來的額外成本促使它們重新評估採購籌資策略、供應商多元化和近岸外包方案。因此，採購團隊和營運負責人正專注於分析到岸成本、總擁有成本和庫存彈性，以降低潛在的價格波動和供應中斷風險。

這些動態也影響產品藍圖和商業化策略。擁有全球分銷網路的公司正在評估定價模式和合約條款，以保護利潤率並在關鍵地區保持競爭力。同時，策略夥伴關係和對區域製造的投資正日益受到關注，被視為避免貿易摩擦和縮短前置作業時間的途徑。對於臨床和研究機構而言，由於新的關稅相關成本壓力，它們需要重新評估資本預算和耗材供應承諾，因此採購週期可能會延長，這也使得透明的價值提案和可靠的衛生經濟學證據變得更加重要。

可操作的細分框架，將設備原型、臨床適應症、護理環境、實行技術和患者人口統計特徵聯繫起來，為產品和測試設計提供資訊。

有效的市場區隔對於了解創新將在哪些領域產生最大的臨床和商業性影響至關重要，而從設備類型、應用、最終用戶、技術和年齡層等多個維度進行細緻分析，可以揭示不同的應用管道。按設備類型分類，市場包括生物回饋療法系統、外骨骼、功能性電刺激設備、神經調控設備和虛擬實境系統。在生物回饋療法系統中，肌電生物回饋療法和壓力生物回饋療法有所區別；外骨骼分為下肢和上肢兩種配置；功能性電刺激設備分為植入式和表面式；神經調控設備分為侵入式和非侵入式；虛擬實境系統則分為身臨其境型和非身臨其境型。依應用分類，臨床適應症包括腦性麻痹、多發性硬化症、巴金森氏症、脊髓損傷和中風。腦性麻痹亞型包括共濟失調型、運動障礙型和痙攣型。多發性硬化症的病程分為進行型和復發緩解型。帕金森氏症通常分為晚期和早期。脊髓損傷分為完全性損傷和不完全性損傷。中風病例依病因分為出血性和缺血性。按最終用戶分類，部署地點涵蓋診所、居家照護、醫院、復健中心和研究機構。診所分為綜合診所和專科診所，居家照護分為輔助生活和自我管理，醫院分為私立醫院和公立醫院，復健中心分為住院部和門診部，研究機構分為學術型和私立型。依技術分類，關鍵技術包括腦機介面、機器人技術、經顱直流電刺激、經顱磁刺激和虛擬實境。腦機介面進一步分為侵入式和非侵入式兩種模式，機器人技術分為末端執行器系統和外骨骼系統，經顱直流電刺激（TDS）分為陽極模式和陰極模式，經顱磁刺激（TMS）分為dTMS和rTMS兩種變體，虛擬實境技術分為身臨其境型和非身臨其境型。就年齡層而言，患者群體涵蓋成人、老年人和兒童。成人通常分為18-40歲、41-64歲及65歲以上三個年齡層；老年患者分為65-74歲、75-84歲及85歲以上三個年齡層；兒童包括青少年、兒童及新生兒。

這些細分維度的重疊為產品開發和臨床檢驗創造了多個方向。例如，專為門診復健中心早期帕金森氏症患者設計的身臨其境型虛擬實境系統，與旨在用於居家照護中不完全性脊髓損傷復健的表面功能性電刺激設備，其臨床證據和商業化路徑將截然不同。因此，企業必須根據設備類型、治療適應症、護理環境、實行技術和患者年齡層的具體交集，調整其監管策略、臨床研究設計和實施流程，以最大限度地提高產品的普及率和治療相關性。

影響美洲、歐洲、中東和非洲以及亞太地區臨床應用、報銷方式和生產策略的區域性因素

區域動態影響臨床應用、報銷政策和供應鏈策略，三大宏觀區域各自呈現不同的機會和挑戰。在美洲，分散的醫療服務體系、完善的支付系統和活躍的創業投資活動為技術先進的醫療器械的商業化提供了支持，但聯邦和私人支付方在報銷方面的差異，使得協調衛生經濟學證據和區域市場推廣計劃變得至關重要。歐洲、中東和非洲的特點是管理體制、基礎設施和公私醫療服務提供者的多樣性，這需要靈活的分銷模式和夥伴關係策略。在部分地區，如果證據達到政策門檻，集中化的報銷機構可以加速技術應用；而在中東和非洲的其他地區，則需要進行區域試點測試以驗證可行性。亞太地區展現出快速的都市區應用、強大的製造能力和不斷發展的報銷管道。此外，該地區對可擴展、經濟高效的解決方案有著很高的需求，這些解決方案能夠滿足龐大的患者群體和多樣化的醫療基礎設施的需求。

在這些地區，相關人員必須考慮臨床實踐模式、看護者配備和數位化醫療應對力程度的差異。因此，整合區域特定臨床檢驗、報銷文件和培訓項目的打入市場策略將有助於實現永續推廣。此外，建立策略性區域夥伴關係、投資本地監管專業知識以及進行有針對性的價值溝通，對於彌合這些不同地區之間的臨床證據與採購決策之間的鴻溝至關重要。

競爭動態和能力需求將影響神經復健設備生態系中的領導地位、夥伴關係模式和附加價值服務差異化。

神經復健設備生態系統的競爭動態由成熟的醫療技術公司、專注於特定領域的精品開發商、學術衍生公司以及跨行業新秀共同構成。主要企業強調其多學科研發能力、完善的監管管道和廣泛的臨床證據項目，而規模較小的創新者則往往專注於特定適應症、顛覆性技術以及能夠加速臨床檢驗的策略聯盟。在整個競爭格局中，與學術中心、大型醫療系統或零件供應商合作已成為加速產品迭代和增強臨床可靠性的核心機制。

此外，差異化服務模式正逐漸成為競爭優勢。將設備與遠端監測、分析和臨床支援軟體平台結合的公司，能夠為那些重視長期療效評估的購買者提供更高的感知價值。圍繞著演算法、感測器融合和治療交付的智慧財產權，以及在不同患者群體中展現可重複療效提升的能力，都會影響競爭地位。因此，各公司正增加對療效研究、支付方合作和可擴展生產的投資，以增強商業性防禦能力。

領導者必須採取切實可行的策略措施，將臨床證據、模組化產品開發、供應鏈韌性和支付方參與相結合，以實現永續成長。

產業領導者應採取雙管齊下的策略，平衡近期商業化與長期平台開發。首先，優先針對具有高影響力的適應症和擁有成熟報銷管道的醫療環境，產生臨床證據，從而打造能夠推動支付方參與和臨床醫生支持的標竿案例。同時，投資於模組化產品架構和支援迭代更新的軟體服務，使企業能夠在無需徹底重新設計硬體的情況下，擴展治療適應症和護理路徑。

第二，我們正透過策略性供應商多元化、投資區域製造以及靈活的採購協議來增強供應鏈韌性，以降低關稅引發的成本波動和零件短缺的風險。第三，我們正與醫療系統、復健網路和學術中心建立夥伴關係，共同開發培訓課程、遠距監測工作流程和價值文件，使臨床結果與採購需求相符。最後，我們將可靠的上市後證據收集和衛生經濟學模型融入商業營運，將臨床結果轉化為對支付方提案相關的價值主張，從而加快醫保覆蓋決策和機構採購。

透過透明的多方法研究途徑，結合一手臨床訪談、專家文獻綜述、監管審查和供應商格局分析，以獲得可靠的洞察。

我們的研究途徑結合了多方資訊來源收集和專家諮詢，建構了一個嚴謹且可重複的分析基礎。主要研究包括對臨床醫生、採購負責人和技術開發人員進行結構化訪談，以了解實際應用中的挑戰、臨床優先事項和促進因素。次要研究則檢驗了同儕審查的臨床文獻、監管指導文件和公開的技術規格中的設備特性和臨床應用案例。此外，供應商格局分析和專利分析也讓我們深入了解了技術差異化和智慧財產權趨勢。

數據綜合分析將定性見解與定量營運指標（例如臨床試驗活動、監管核准和已發表的健康結果）進行三角驗證。透過應用標準化標準（包括證據權重、假設透明度和重複的同儕檢驗） ，檢驗了調查方法的嚴謹性。這種方法確保結論能夠反映臨床實際情況、監管限制以及與相關人員在整個開發、部署和採購生命週期中相關的商業性需求。

整合技術整合、政策轉變和商業需求，為將神經復健創新轉化為臨床影響的策略重點提供基礎。

總之，神經復健設備生態系統正從一系列獨立技術的集合演變為一個以持續護理、可驗證的療效和可擴展的交付為優先的綜合治療平台。包括機器人技術、神經調控、腦機介面和身臨其境型環境在內的技術融合，在拓展治療選擇的同時，也提高了臨床檢驗和互通性的門檻。同時，政策變化、價格波動和區域醫療保健差異正在重塑供應鏈、定價策略和產品上市時間。

為了應對這一複雜的局面，相關人員需要將產品設計與特定的臨床路徑相匹配，投資於能夠引起支付方和醫療服務提供方共鳴的證據，並建立能夠適應地緣政治和監管變化的穩健營運模式。那些將嚴謹的臨床科學與務實的商業化策略和合作夥伴關係相結合的公司，將更有能力將創新轉化為持續的患者獲益和組織發展。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 引入封閉回路型神經調控系統進行個人化中風復健治療
  • 將穿戴式外骨骼與腦機介面結合，以增強運動後恢復。
  • 利用虛擬實境和遊戲化技術提高患者參與神經復健計畫的積極性
  • 超音波神經調控技術在神經系統疾病非侵入性治療的應用進展
  • 具備遠端監控和遠端醫療功能的家用機器人復健設備發展迅速
  • 人工智慧驅動的預測分析的出現，為最佳化個人化神經復健治療管道奠定了基礎
  • 開發一種可植入式神經探針，實現即時監測和自適應刺激通訊協定

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 神經復健設備市場（依設備類型分類）

  • 生物回饋療法系統
    • 肌電生物回饋療法
    • 壓力生物回饋療法
  • 外骨骼
    • 下肢
    • 上肢
  • 功能性電刺激設備
    • 嵌入式
    • 表面
  • 神經調節裝置
    • 侵入性
    • 非侵入性
  • 虛擬實境系統
    • 身臨其境型
    • 非身臨其境型

第9章 按應用分類的神經復健設備市場

  • 腦性麻痹
    • 共濟失調
    • 運動障礙
    • 痙攣
  • 多發性硬化症
    • 進步
    • 復發緩解型
  • 帕金森氏症
    • 晚期
    • 早期的
  • 脊髓損傷
    • 完成
    • 未完成
  • 中風
    • 出血性
    • 缺血性

第10章 依最終使用者分類的神經復健設備市場

  • 診所
    • 一般的
    • 專業
  • 居家醫療
    • 輔助生活設施
    • 自我管理
  • 醫院
    • 私人的
    • 公共
  • 復健中心
    • 住院治療
    • 門診
  • 研究所
    • 學術的
    • 私人的

第11章 按科技分類的神經復健設備市場

  • 腦機介面
    • 侵入性
    • 非侵入性
  • 機器人技術
    • 末端執行器
    • 外骨骼
  • 經顱直流電刺激
    • 陽極
    • 陰極
  • 經顱磁刺激
    • dTMS
    • rTMS
  • 虛擬實境
    • 身臨其境型
    • 非身臨其境型

第12章 按年齡層別分類的神經復健設備市場

  • 成人
    • 18至40歲
    • 41至64歲
    • 65歲或以上
  • 老年人
    • 65-74歲
    • 75至84歲
    • 85歲或以上
  • 孩子們
    • 青春期
    • 嬰兒
    • 新生

第13章 各地區神經復健設備市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 神經復健設備市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國神經復健設備市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Medtronic plc
    • Bioness, Inc.
    • Hocoma AG
    • Tyromotion GmbH
    • Ekso Bionics Operations, Inc.
    • ReWalk Robotics Ltd.
    • Myomo, Inc.
    • Bionik Laboratories Corp.
    • Cyberdyne Inc.
    • Hasomed GmbH
Product Code: MRR-710B1F0AC5A5

The Neurorehabilitation Devices Market is projected to grow by USD 2.62 billion at a CAGR of 7.97% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.42 billion
Estimated Year [2025] USD 1.53 billion
Forecast Year [2032] USD 2.62 billion
CAGR (%) 7.97%

Comprehensive orientation to contemporary clinical pressures, stakeholder expectations, and technology-driven pathways reshaping neurorehabilitation device adoption and care delivery

Neurorehabilitation devices sit at the intersection of clinical need and rapid technological advancement, driven by the imperative to restore function, reduce disability, and improve quality of life for patients with neurological conditions. Clinicians increasingly demand solutions that integrate precise diagnostics, adaptive therapy delivery, and measurable outcomes, while payers and providers seek demonstrable value through improved functional independence and reduced long-term care costs. As a result, developers are prioritizing interoperability, user-centered design, and evidence generation to shorten the path from innovation to clinical adoption.

Across diverse care settings, from acute hospitals to outpatient rehabilitation centers and home-based care, the emphasis is shifting toward devices that enable continuity of care and remote monitoring. Consequently, regulatory strategy, clinical validation, and real-world performance data have become core determinants of commercial success. In light of these dynamics, stakeholders must reconcile long development cycles and complex reimbursement environments with a growing expectation for personalization and scalable clinical workflows.

How converging technologies, decentralized care models, and value-driven evidence requirements are catalyzing a paradigm shift in neurorehabilitation device development and delivery

The neurorehabilitation landscape is undergoing multiple transformative shifts that are rewriting how therapies are developed, reimbursed, and delivered. Advances in sensing, actuation, and machine learning have enabled devices to offer adaptive therapy regimens that respond to patient progress in near real time. Simultaneously, the convergence of robotics, neuromodulation, brain-computer interfaces, and immersive virtual environments is expanding therapeutic possibilities beyond traditional boundaries, enabling multi-modal interventions that target motor, cognitive, and sensory recovery.

At the same time, clinical practice patterns are evolving toward decentralized care models. This shift increases demand for lightweight, user-friendly devices that support home-based therapy and clinician-supervised remote sessions. Payers and health systems are responding to population aging and rising chronic neurological disease prevalence by prioritizing interventions that demonstrate long-term functional gains and reduced downstream costs. As a result, product development roadmaps emphasize reimbursement strategy, longitudinal outcome tracking, and evidence generation to validate sustained clinical impact. Ultimately, these combined forces are accelerating a transition from discrete devices to integrated care platforms that connect patients, clinicians, and data in continuous therapeutic ecosystems.

Implications of 2025 tariff adjustments on supply chains, procurement strategies, and regional manufacturing considerations for neurorehabilitation device stakeholders

Tariff policies and trade measures instituted in 2025 introduced new operational and strategic considerations for manufacturers, suppliers, and health systems that rely on cross-border supply chains for components and finished devices. For firms that import specialized electronics, sensors, and actuation systems, the added costs associated with tariffs have prompted reassessments of sourcing strategy, supplier diversification, and nearshoring options. In turn, procurement teams and operations leaders have increased focus on landed cost analysis, total cost of ownership, and inventory resilience to mitigate potential price volatility and supply disruptions.

These dynamics have also influenced product roadmaps and commercialization tactics. Companies with global distribution networks are evaluating pricing models and contractual terms to preserve competitiveness in key regions while protecting margins. Meanwhile, strategic partnerships and regional manufacturing investments have gained traction as a way to circumvent trade frictions and shorten lead times. For clinical and research institutions, procurement cycles may lengthen as organizations re-evaluate capital budgets and consumable supply commitments in light of new tariff-related cost pressures, which reinforces the need for transparent value propositions and robust health economic evidence.

Actionable segmentation framework linking device archetypes, clinical indications, care settings, enabling technologies, and patient age groups to inform product and trial design

Effective segmentation is critical to understanding where innovations will have the greatest clinical and commercial impact, and a nuanced view across device type, application, end user, technology, and age group reveals distinct adoption pathways. Based on device type, the landscape includes biofeedback systems, exoskeletons, functional electrical stimulation devices, neuromodulation devices, and virtual reality systems; within biofeedback systems, distinctions arise between EMG biofeedback and pressure biofeedback, while exoskeletons bifurcate into lower limb and upper limb configurations, functional electrical stimulation devices differentiate between implantable and surface approaches, neuromodulation devices are classified as invasive or noninvasive, and virtual reality systems range from immersive to nonimmersive experiences. Based on application, clinical indications encompass cerebral palsy, multiple sclerosis, Parkinson's disease, spinal cord injury, and stroke; cerebral palsy subtypes include ataxic, dyskinetic, and spastic presentations, multiple sclerosis courses separate into progressive and relapsing remitting forms, Parkinson's disease is commonly considered in advanced and early stages, spinal cord injury is categorized as complete or incomplete, and stroke cases are differentiated into hemorrhagic and ischemic etiologies. Based on end user, deployments vary across clinics, home care, hospitals, rehabilitation centers, and research institutes; clinics split into general and specialty practices, home care is distinguished between assisted living and self-managed contexts, hospitals differ by private and public status, rehabilitation centers operate as inpatient or outpatient facilities, and research institutes are either academic or private. Based on technology, key enablers include brain-computer interfaces, robotics, transcranial direct current stimulation, transcranial magnetic stimulation, and virtual reality; brain-computer interfaces further separate into invasive and noninvasive modalities, robotics divides into end effector and exoskeleton systems, transcranial direct current stimulation is categorized into anodal and cathodal modes, transcranial magnetic stimulation appears as dTMS and rTMS variants, and virtual reality technologies split into immersive and nonimmersive formats. Based on age group, patient segments span adult, geriatric, and pediatric populations; adults are commonly profiled across ages 18 to 40, 41 to 64, and 65 plus, geriatric cohorts are often delineated as 65 to 74, 75 to 84, and 85 plus, and pediatric patients encompass adolescent, childhood, and neonatal stages.

Taken together, these layered segmentation dimensions create multiple vectors for product development and clinical validation. For example, an immersive virtual reality system designed for early-stage Parkinson's disease in an outpatient rehabilitation center will follow a different clinical evidence and commercialization path than a surface functional electrical stimulation device intended for incomplete spinal cord injury rehabilitation in home-based care. Therefore, companies must align regulatory strategy, clinical study designs, and implementation workflows to the precise intersection of device type, therapeutic indication, care setting, enabling technology, and patient age group to maximize adoption and therapeutic relevance.

Regional considerations influencing clinical adoption, reimbursement approaches, and manufacturing strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape clinical adoption, reimbursement policy, and supply chain strategy, and three macro regions present distinct opportunities and constraints. In the Americas, decentralized healthcare delivery, advanced payer systems, and strong venture capital activity support commercialization of technologically sophisticated devices, but heterogeneity in reimbursement across federal and private payers requires tailored health economic evidence and localized market access plans. Europe, Middle East & Africa features diverse regulatory regimes, variable infrastructure, and a mix of public and private providers that necessitate flexible distribution models and partnership strategies; in parts of the region, centralized reimbursement authorities can accelerate uptake where evidence meets policy thresholds, whereas other areas demand localized pilots to demonstrate feasibility. The Asia-Pacific region exhibits rapid adoption in urban centers, strong manufacturing capabilities, and evolving reimbursement pathways; it also presents high demand for scalable, cost-effective solutions that can be adapted to large patient volumes and diverse care infrastructures.

Across these regions, stakeholders must consider differences in clinical practice patterns, caregiver availability, and digital health readiness. Consequently, go-to-market strategies that integrate region-specific clinical validation, reimbursement dossiers, and training programs will be better positioned to achieve sustainable adoption. Furthermore, strategic regional partnerships, investments in local regulatory expertise, and targeted value communication are essential to bridge clinical evidence with procurement decision-making across these varied geographies.

Competitive dynamics and capability imperatives shaping leadership positions, partnership models, and value-added service differentiation across the neurorehabilitation device ecosystem

Competitive dynamics in the neurorehabilitation device ecosystem are defined by a blend of established medtech firms, specialized boutique developers, academic spinouts, and cross-industry entrants. Leading companies emphasize multi-disciplinary R&D capabilities, robust regulatory pathways, and broad clinical evidence programs, while smaller innovators often focus on niche indications, disruptive technologies, and strategic collaborations to accelerate clinical validation. Across the competitive landscape, alliance formation-whether with academic centers, large health systems, or component suppliers-has become a core mechanism to accelerate product iteration and strengthen clinical credibility.

In addition, differentiated service models are emerging as a competitive lever. Firms that combine devices with software platforms for remote monitoring, analytics, and clinician support can offer higher perceived value to purchasers who prioritize longitudinal outcome measurement. Intellectual property around algorithms, sensor fusion, and therapeutic dosing also influences competitive positioning, as does the ability to demonstrate reproducible functional gains in heterogeneous patient populations. As a result, companies are increasingly investing in outcomes research, payer engagement, and scalable manufacturing to fortify commercial defensibility.

Practical strategic imperatives for leaders to align clinical evidence, modular product development, supply chain resilience, and payer engagement for sustainable growth

Industry leaders should adopt a dual-focus strategy that balances near-term commercialization with long-term platform development. First, prioritize clinical evidence generation targeted to high-impact indications and care settings where reimbursement pathways are mature, thereby creating reference cases that facilitate payer engagement and clinician advocacy. Concurrently, invest in modular product architectures and software-enabled services that can be iteratively updated, allowing companies to expand therapeutic indications and care pathways without full hardware redesigns.

Second, strengthen supply chain resilience through strategic supplier diversification, regional manufacturing investments, and flexible procurement contracts to reduce exposure to tariff-driven cost fluctuations and component shortages. Third, cultivate partnerships with health systems, rehabilitation networks, and academic centers to co-develop training curricula, remote monitoring workflows, and value dossiers that align clinical outcomes with procurement requirements. Finally, integrate robust post-market evidence capture and health economic modeling into commercial operations to translate clinical performance into payer-relevant value propositions, thereby accelerating coverage decisions and institutional procurement.

Transparent, multi-method research approach combining primary clinical interviews, technical literature synthesis, regulatory review, and supplier landscape analysis for robust insights

The research approach combines multi-source evidence gathering with expert consultation to build a rigorous, reproducible foundation for analysis. Primary research included structured interviews with clinicians, procurement leaders, and technology developers to capture real-world implementation challenges, clinical priorities, and adoption drivers. Secondary research drew on peer-reviewed clinical literature, regulatory guidance documents, and publicly available technical specifications to validate device capabilities and clinical use cases. In addition, supplier landscape mapping and patent analysis provided insight into technological differentiation and intellectual property trends.

Data synthesis involved triangulating qualitative insights with quantitative operational indicators such as clinical trial activity, regulatory approvals, and published health outcomes where available. Throughout the process, methodological rigor was maintained by applying standardized criteria for evidence weighting, transparency in assumptions, and iterative validation with domain experts. This approach ensures that conclusions reflect clinical realities, regulatory constraints, and commercial imperatives relevant to stakeholders across the development, deployment, and procurement lifecycle.

Synthesis of technological convergence, policy shifts, and operational imperatives informing strategic priorities for translating neurorehabilitation innovation into clinical impact

In conclusion, the neurorehabilitation device ecosystem is evolving from a collection of discrete technologies into integrated therapeutic platforms that prioritize continuity of care, demonstrable outcomes, and scalable delivery. Technological convergence across robotics, neuromodulation, brain-computer interfaces, and immersive environments is expanding therapeutic options while also raising the bar for clinical validation and interoperability. Meanwhile, policy shifts, tariff dynamics, and regional healthcare variances are reshaping supply chains, pricing strategies, and commercialization timelines.

As stakeholders navigate this complexity, success will hinge on aligning product design with specific clinical pathways, investing in evidence that resonates with payers and providers, and building resilient operational models that can adapt to geopolitical and regulatory changes. Those who combine rigorous clinical science with pragmatic commercialization strategies and cooperative partnerships will be best positioned to translate innovation into sustained patient benefit and organizational growth.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of closed-loop neuromodulation systems for personalized stroke rehabilitation therapy
  • 5.2. Integration of brain-computer interfaces with wearable exoskeletons to enhance motor recovery outcomes
  • 5.3. Utilization of virtual reality and gamification to drive patient engagement in neurorehabilitation programs
  • 5.4. Advancements in ultrasound neuromodulation techniques for noninvasive treatment of neurological disorders
  • 5.5. Growth of home-based robotic rehabilitation devices offering remote monitoring and teletherapy capabilities
  • 5.6. Emergence of AI-driven predictive analytics for optimizing personalized neurorehabilitation treatment pathways
  • 5.7. Development of implantable neural probes enabling real-time monitoring and adaptive stimulation protocols

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurorehabilitation Devices Market, by Device Type

  • 8.1. Biofeedback System
    • 8.1.1. EMG Biofeedback
    • 8.1.2. Pressure Biofeedback
  • 8.2. Exoskeleton
    • 8.2.1. Lower Limb
    • 8.2.2. Upper Limb
  • 8.3. Functional Electrical Stimulation Device
    • 8.3.1. Implantable
    • 8.3.2. Surface
  • 8.4. Neuromodulation Device
    • 8.4.1. Invasive
    • 8.4.2. Noninvasive
  • 8.5. Virtual Reality System
    • 8.5.1. Immersive
    • 8.5.2. Nonimmersive

9. Neurorehabilitation Devices Market, by Application

  • 9.1. Cerebral Palsy
    • 9.1.1. Ataxic
    • 9.1.2. Dyskinetic
    • 9.1.3. Spastic
  • 9.2. Multiple Sclerosis
    • 9.2.1. Progressive
    • 9.2.2. Relapsing Remitting
  • 9.3. Parkinson's Disease
    • 9.3.1. Advanced Stage
    • 9.3.2. Early Stage
  • 9.4. Spinal Cord Injury
    • 9.4.1. Complete
    • 9.4.2. Incomplete
  • 9.5. Stroke
    • 9.5.1. Hemorrhagic
    • 9.5.2. Ischemic

10. Neurorehabilitation Devices Market, by End User

  • 10.1. Clinics
    • 10.1.1. General
    • 10.1.2. Specialty
  • 10.2. Home Care
    • 10.2.1. Assisted Living
    • 10.2.2. Self Managed
  • 10.3. Hospitals
    • 10.3.1. Private
    • 10.3.2. Public
  • 10.4. Rehabilitation Centers
    • 10.4.1. Inpatient
    • 10.4.2. Outpatient
  • 10.5. Research Institutes
    • 10.5.1. Academic
    • 10.5.2. Private

11. Neurorehabilitation Devices Market, by Technology

  • 11.1. Brain Computer Interface
    • 11.1.1. Invasive
    • 11.1.2. Noninvasive
  • 11.2. Robotics
    • 11.2.1. End Effector
    • 11.2.2. Exoskeleton
  • 11.3. Transcranial Direct Current Stimulation
    • 11.3.1. Anodal
    • 11.3.2. Cathodal
  • 11.4. Transcranial Magnetic Stimulation
    • 11.4.1. dTMS
    • 11.4.2. rTMS
  • 11.5. Virtual Reality
    • 11.5.1. Immersive
    • 11.5.2. Nonimmersive

12. Neurorehabilitation Devices Market, by Age Group

  • 12.1. Adult
    • 12.1.1. 18 To 40
    • 12.1.2. 41 To 64
    • 12.1.3. 65 Plus
  • 12.2. Geriatric
    • 12.2.1. 65 To 74
    • 12.2.2. 75 To 84
    • 12.2.3. 85 Plus
  • 12.3. Pediatric
    • 12.3.1. Adolescent
    • 12.3.2. Childhood
    • 12.3.3. Neonatal

13. Neurorehabilitation Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Neurorehabilitation Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Neurorehabilitation Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Medtronic plc
    • 16.3.2. Bioness, Inc.
    • 16.3.3. Hocoma AG
    • 16.3.4. Tyromotion GmbH
    • 16.3.5. Ekso Bionics Operations, Inc.
    • 16.3.6. ReWalk Robotics Ltd.
    • 16.3.7. Myomo, Inc.
    • 16.3.8. Bionik Laboratories Corp.
    • 16.3.9. Cyberdyne Inc.
    • 16.3.10. Hasomed GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS NEUROREHABILITATION DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NEUROREHABILITATION DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NEUROREHABILITATION DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. NEUROREHABILITATION DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEUROREHABILITATION DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY BIOFEEDBACK SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EMG BIOFEEDBACK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EMG BIOFEEDBACK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EMG BIOFEEDBACK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EMG BIOFEEDBACK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EMG BIOFEEDBACK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EMG BIOFEEDBACK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRESSURE BIOFEEDBACK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRESSURE BIOFEEDBACK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRESSURE BIOFEEDBACK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRESSURE BIOFEEDBACK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRESSURE BIOFEEDBACK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRESSURE BIOFEEDBACK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EXOSKELETON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY LOWER LIMB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY LOWER LIMB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY LOWER LIMB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY LOWER LIMB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY LOWER LIMB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY LOWER LIMB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY UPPER LIMB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY UPPER LIMB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY UPPER LIMB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY UPPER LIMB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY UPPER LIMB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY UPPER LIMB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY FUNCTIONAL ELECTRICAL STIMULATION DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMPLANTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMPLANTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMPLANTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMPLANTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMPLANTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMPLANTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SURFACE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SURFACE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SURFACE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SURFACE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SURFACE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SURFACE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NEUROMODULATION DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONINVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONINVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONINVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONINVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONINVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONINVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY VIRTUAL REALITY SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMMERSIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMMERSIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMMERSIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMMERSIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMMERSIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY IMMERSIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONIMMERSIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONIMMERSIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONIMMERSIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONIMMERSIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONIMMERSIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY NONIMMERSIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CEREBRAL PALSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ATAXIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ATAXIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ATAXIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ATAXIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ATAXIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ATAXIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DYSKINETIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DYSKINETIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DYSKINETIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DYSKINETIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DYSKINETIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY DYSKINETIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPASTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPASTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPASTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPASTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPASTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPASTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PROGRESSIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PROGRESSIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PROGRESSIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PROGRESSIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PROGRESSIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PROGRESSIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RELAPSING REMITTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RELAPSING REMITTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RELAPSING REMITTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RELAPSING REMITTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RELAPSING REMITTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RELAPSING REMITTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EARLY STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EARLY STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EARLY STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL CORD INJURY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL CORD INJURY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY COMPLETE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY COMPLETE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY COMPLETE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY COMPLETE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY COMPLETE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY COMPLETE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INCOMPLETE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INCOMPLETE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INCOMPLETE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INCOMPLETE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INCOMPLETE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INCOMPLETE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY STROKE, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY STROKE, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HEMORRHAGIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HEMORRHAGIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HEMORRHAGIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HEMORRHAGIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HEMORRHAGIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HEMORRHAGIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ISCHEMIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ISCHEMIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ISCHEMIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ISCHEMIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ISCHEMIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ISCHEMIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GENERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GENERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GENERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GENERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GENERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY GENERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPECIALTY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPECIALTY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPECIALTY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPECIALTY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPECIALTY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SPECIALTY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ASSISTED LIVING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ASSISTED LIVING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ASSISTED LIVING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ASSISTED LIVING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ASSISTED LIVING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY ASSISTED LIVING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SELF MANAGED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SELF MANAGED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SELF MANAGED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SELF MANAGED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SELF MANAGED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY SELF MANAGED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRIVATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRIVATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRIVATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PRIVATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PUBLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PUBLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PUBLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY PUBLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REHABILITATION CENTERS, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REHABILITATION CENTERS, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY INPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY OUTPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL NEUROREHABILITATION DEVICES MARKET SIZE, BY RESEARCH INS